$REGN

REGENERON PHARMACEUTICALS, INC.

3
8
1

No SEC Form 4 filings for $REGN in the last 30 days.

Med

New Ebola sub-strain jumped 'from fruit bats' to humans - as Congo records more than 200 deaths while Uganda confirms three new cases

Researchers say a new Bundibugyo Ebola sub-strain in the Democratic Republic of Congo may have transferred from wildlife to humans, with fruit bats considered a likely source but not confirmed. WHO upgraded the threat to “very high.” As of the report, 204 deaths and ~870 infections are estimated in the DRC; Uganda confirmed three new cases (five total, one death). Existing Zaire-focused vaccines may not fit; WHO and partners are preparing trials and adapting treatments.

The Bull Case For Vertex Pharmaceuticals (VRTX) Could Change Following Health Canada’s Review Of Suzetrigine

Health Canada has accepted Vertex Pharmaceuticals' New Drug Submission for suzetrigine, a non-opioid acute pain inhibitor, for review. This development could expand Vertex's market beyond the U.S. and is expected to contribute to the company's 2026 revenue goals. While not immediately transformative, the review helps diversify Vertex's portfolio beyond cystic fibrosis and supports its long-term revenue and earnings growth projections, which suggest a significant upside to its current stock price.

The Escalator: Amgen, CG Life, Cosette Pharmaceuticals and more

This article, "The Escalator," details recent personnel changes and key events across the pharma, biotech, and medical marketing industries. It highlights new hires at companies like Amgen, CG Life, and Cosette Pharmaceuticals, executive elevations within regulatory bodies, and significant board appointments. The piece also covers notable departures, miscellaneous industry news including FDA analyses, political actions, and philanthropic partnerships.